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The Efficacy, Safety, and Immunogenicity 
of Switching Between Reference 
Biopharmaceuticals and Biosimilars:  
A Systematic Review
Liese Barbier1,*, Hans C. Ebbers2, Paul Declerck1, Steven Simoens1, Arnold G. Vulto1,3,† and  Isabelle Huys1,†
To date, no consensus exists among stakeholders about switching patients between reference biological products 
(RPs) and biosimilars, which may have been curbing the implementation of biosimilars in clinical practice. This study 
synthesizes the available data on switching and assesses whether switching patients from a RP to its biosimilar or vice 
versa affects efficacy, safety, or immunogenicity outcomes. A total of 178 studies, in which switch outcomes from a 
RP to a biosimilar were reported, was identified. Data were derived from both randomized controlled trials and real-
world evidence. Despite the limitations stemming from a lack of a robust design for most of the studies, the available 
switching data do not indicate that switching from a RP to a biosimilar is associated with any major efficacy, safety, 
or immunogenicity issues. Some open-label and observational studies reported increased discontinuation rates after 
switching, which were mainly attributed to nocebo effects. Involvement of the prescriber in any decision to switch 
should remain and attention should be paid to the mitigation of a potential nocebo effect.
Following the expiry of exclusivity rights on original biological 
medicines (further called the reference products (RPs)), the mar-
ket opens up for biosimilar versions. Due to the intrinsic vari-
ability that is inherent to biological medicines and the complex 
manufacturing process of these products, a biosimilar cannot be 
an exact copy to the RP, but needs to demonstrate that it is a highly 
similar version of the RP. As defined by the European Medicines 
Agency (EMA), a biosimilar is “a biological medicinal product 
that contains a version of the active substance of an already au-
thorized original biological medicinal product in the European 
Economic Area. Similarity to the reference medicinal product in 
terms of quality characteristics, biological activity, safety, and effi-
cacy based on a comprehensive comparability exercise needs to be 
established.”1
Since the authorization of the first biosimilar in 2006 in Europe 
(somatropin, Omnitrope by Sandoz GmbH), > 50 biosimilars for 
a wide range of products and therapeutic areas have been approved 
in the European Union (EU).2 The first wave of approved biosim-
ilars included mainly relatively small therapeutic proteins, such as 
hormones (e.g., somatropin and insulin glargine) and growth fac-
tors (e.g., filgrastim and epoetin). Over the last years, more com-
plex biosimilars, such as monoclonal antibodies (mAbs) and fusion 
proteins used in rheumatology, gastroenterology, and oncology, 
have been approved and entered the market in Europe.2 Since the 
first biosimilar approval in 2015 in the United States (filgrastim, 
Zarxio by Sandoz), the US Food and Drug Administration (FDA) 
approved > 20 biosimilar products.3 An overview of approved bio-
similars in Europe and the United States can be found in Table 1.
The market entry of biosimilars can play an important role in 
containing escalating healthcare expenditures, as they can be of-
fered at lower prices than the RP and lead to price competition. 
The adoption of biosimilars can also lead to increased patient ac-
cess to biological treatments and free healthcare budgets for the 
reimbursement of innovative medicines.4
An approved biosimilar is similar in efficacy, safety, and quality 
to the RP and any observed differences are deemed clinically irrel-
evant.1 Therefore, biological treatment of a bio-naïve patient (i.e., 
a patient without previous treatment with a particular biological 
medicine) can be initiated with a corresponding biosimilar with-
out any efficacy or safety concerns, other than those proclaimed for 
the RP. However, the case of switching patients under treatment 
with the RP to its biosimilar has been questioned and there are still 
concerns remaining among many healthcare professionals (HCPs) 
and patients.5,6 Concerns have been raised that switching between 
highly similar, but not identical versions of a biological medicine, 
may lead to an increase in immunogenicity, due to the subsequent 
exposure to potentially different sets of epitopes (for example, due 
to differences in glycosylation between the products7),8 although 
this has never been observed in clinical studies. The formation of 
anti-drug antibodies (ADAs), although these uncommonly result 
in a clinically harmful effect, could subsequently lead to safety is-
sues or a loss of efficacy (LOE) to the treatment.9
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Table 1 Overview of approved biosimilars in Europe and the United States
Product Europe United States
INN Reference product Biosimilar(s)2 Reference product Biosimilar(s)a,3
Adalimumab Humira Amgevita
Halimatoz/Hefiya/Hyrimoz
Hulio
Idacio/Kromeya
Imraldi
Humira Amjevita (adalimumab-atto)
Cyltezo (adalimumab-adbm)
Hyrimoz (adalimumab-adaz)
Bevacizumab Avastin Mvasi
Zirabev
Avastin Mvasi (adalimumab-awwb)
Enoxaparin Clexane Inhixa
Thorinane
Lovenox –
Epoetin alfa
Epoetin zeta
Eprex Abseamed
Binocrit
Epoetin Alfa Hexal
Retacrit
Silapo
Epogen/Procrit Retacrit (epoetin alfa-epbx)
Etanercept Enbrel Benepali
Erelzi
Enbrel Erelzi (etanercept-szzs)
Eticovo (etanercept-ykro)
Filgrastim Neupogen Accofil, Grastofil
Filgrastim Hexal/Zarzio
Nivestim
Ratiograstim/Tevagrastim
Neupogen Zarxio (filgrastim-sndz)
Nivestym (filgrastim-aafi)
Follitropin alfa Gonal-F Bemfola
Ovaleap
Gonal-F –
Infliximab Remicade Flixabi
Inflextra/Remsima
Zessly
Remicade Inflectra (infliximab-dyyb)
Renflexis (infliximab-abda)
Ixifi (infliximab-qbtx)
Insulin 
glargine
Lantus Abasaglar
Semglee
Lantus –
Insulin lispro Humalog Insulin lispro Sanofi Humalog –
Pegfilgrastim Neulasta Fulphila
Grasustek
Pelgraz
Pelmeg
Udenyca
Ziextenzo
Neulasta Fulphila (pegfilgrastim-jmdb)
Udenyca (pegfilgrastim-cbqv)
Rituximab Mabthera Blitzima/Ritemvia/Rituzena/
Truxima
Rixathon/Riximyo
Rituxan Truxima (rituximab-abbs)
Somatropin Genotropin Omnitrope Genotropin –
Teriparatide Forsteo Movymia
Terrosa
Forteo –
Trastuzumab Herceptin Herzuma
Kanjinti
Ogivri
Ontruzant
Trazimera
Herceptin Herzuma (trastuzumab-pkrb)
Ogivri (trastuzumab-dkst)
Ontruzant (trastuzumab-dttb)
Trazimera (trastuzumab-qyyp)
Europe: Biosimilar candidates are evaluated by the European Medicines Agency and subsequently authorized by the European Commission in case of a positive 
opinion. The centralized marketing authorisation for biosimilars is valid in all EU Member States as well as in the European Economic Area countries Iceland, 
Liechtenstein, and Norway. Over 50 biosimilars have been approved, since the approval of the first biosimilar (biosimilar of somatropin) in 2006.2
United States: Biosimilar candidates are evaluated and subsequently approved by the US Food and Drug Administration (FDA). Over 20 biosimilars haven been 
approved by the FDA, since the approval of the first biosimilar (biosimilar of filgrastim) in 2015.3
INN, international nonproprietary name.
Products separated with a “/” are duplicates of each other (i.e., these products contain identical active substances, but are licensed under a different 
tradename).
aIn the United States, biosimilars of some early biologic drugs, such as somatropin and insulin, have been approved as generics, due to differences between 
the regulatory pathway of some protein originator products (historically approved under the Food, Drug, and Cosmetic (FD&C) Act) and later originator biological 
medicines. The FDA will transition these products to be regulated as biologicals under the Public Health Service Act.85 The FDA assigns four-letter suffixes 
to approved reference biologics, biosimilars, and (future) interchangeable biosimilars. Recent FDA draft guidance states that suffixes will not be retroactively 
assigned to previously authorized biologicals without suffix or transition products.86
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KEY CONCEPTS AND TERMINOLOGY
Switching is the act by the treating physician “to exchange one med-
icine for another with the same therapeutic intent.”10 Switching 
can refer to a change between two different molecules (with a 
different international nonproprietary name (INN) e.g., inflix-
imab to adalimumab) or a change between a RP and its biosimilar 
version (e.g., infliximab to CT-P13) or between biosimilars of the 
same RP. Switching from a RP to a biosimilar (or vice versa) or be-
tween biosimilars is also referred to as nonmedical switching (i.e., 
switching merely for cost-saving reasons). Dörner and colleagues 
proposed the term transitioning for this type of switching,11 in an 
effort to delineate the different types of switches reported in the 
literature. In this paper, the term switching refers to the switch 
from a RP to a biosimilar (or vice versa). Automatic substitution is 
“the act of dispensing one medicine instead of another equivalent 
and interchangeable medicine at the pharmacy level without con-
sulting the prescriber.”10 The practice of substitution is regulated 
on a member state level and for biological medicines prohibited or 
advised against in most European countries.12 Interchangeability 
is a characteristic of two medicines and “refers to the possibility of 
exchanging one medicine for another medicine that is expected 
to have the same clinical effect. This could mean replacing a ref-
erence product with a biosimilar (or vice versa) or replacing one 
biosimilar with another,”10 either prior to the start of a biological 
treatment or during (stable) treatment.
Switching and substitution practices and the designation of in-
terchangeability are not regulated on an EU level as prescribing 
practices fall within the responsibilities of the different EU mem-
ber states.10 In the United States, the FDA has created a regulatory 
designation pathway for the scientific evaluation of interchange-
ability. An interchangeable product needs to meet additional re-
quirements in addition to being authorized as a biosimilar.13 For 
the proposed interchangeable product, it needs to be shown that 
it “can be expected to produce the same clinical result as the RP in 
any given patient; and for a product that is administered more than 
once to an individual, the risk in terms of safety or diminished effi-
cacy of alternating or switching between use of the product and its 
RP is not greater than the risk of using the RP without such alter-
nation or switch.”13 According to the Biologics Price Competition 
and Innovation Act (BPCI Act) section 351(k)(4), the pharmacist 
would be allowed to substitute a prescribed biological RP with an 
interchangeable biosimilar without the involvement of the pre-
scriber, if allowed by state laws.13 Thus far, no biosimilars have yet 
been deemed interchangeable by the FDA.3
In 2012, Ebbers et al. investigated the safety of switching between 
therapeutic proteins, addressing the key question surrounding the 
use in practice of biosimilars. The study did not find evidence from 
clinical trial data or postmarketing surveillance (PMS) data that 
switching to and from different biological medicines led to safety 
concerns.14 Since then, many more biosimilars have been approved 
and entered the market.2 Increasingly, national competent author-
ities and HCP organizations formulated guidance about switch-
ing.15 However, switching remains a highly debated topic and the 
arrival of the more complex mAb biosimilars to the market further 
sparked the discussion.8,16 Various biological medicines, especially 
blockbuster mAbs, are used in a chronic setting, stressing the need 
to address these questions in an effort to aid (clinical) decision 
making. Furthermore, the uncertainty about switching limits the 
competition potential of biosimilars to curb the increasing burden 
on healthcare budgets and to increase treatment access for patients.
This systematic literature review aims to synthesize the cur-
rently available data on switching and to  assess the safety, im-
munogenicity, and efficacy of switching between RPs and their 
respective  biosimilar version(s). This review broadens the scope 
of previous studies14,17 by reviewing switch data for biologicals 
of every therapeutic class for which a European market autho-
rization has been granted, more specifically: (i) recombinant 
human  growth hormones (rhGHs), (ii) erythropoietins, (iii) 
granulocyte colony stimulating agents, (iv) insulins, (v) tumor 
necrosis factor alpha inhibitors (anti-TNFs), (vi) gonadotropins, 
(vii) low-molecular-weight heparins, and (viii) mAbs used in on-
cology. Further, we aim to provide a critical insight on the current 
state-of-the-art related to switching. This overview can be useful 
for HCPs and other stakeholders in their (clinical practice) deci-
sion making.
Information on the methodology of this systematic literature re-
view is shown in the online Supplementary Information (Box S1, 
Figure S1, Tables S1 and S2).
STUDIES SWITCHING BETWEEN BIOLOGICAL REFERENCE 
PRODUCTS AND BIOSIMILARS
In total, 178 studies (accumulating up to approximately 21,000 
switched patients) were identified and included in the systematic 
literature review. Switch studies were identified for somatropin, 
epoetin, filgrastim, insulin, anti-TNFs (adalimumab, etanercept, 
and infliximab), follitropin, and mAbs used in oncology (ritux-
imab and trastuzumab). No switch data were identified for pa-
tients treated with enoxaparin. Figure 1 provides an overview of 
the number of identified studies across products. The majority of 
the studies related to switching from an anti-TNF RP to a biosimi-
lar (132/178), and more specifically most studies related to switch-
ing from the infliximab RP to CT-P13 (Remsima/Inflectra).
Different types of study design were identified. Figure 2 illus-
trates the main different switch designs. Most of the studies con-
sisted of a single switch (i.e., patients changed one time from the 
RP to a biosimilar). Only six studies with a multiple switch design 
(i.e., patients changed multiple times between the RP and the bio-
similar, alternating back on forth) were identified.18–23 No studies 
on switching between biosimilars were identified.
Data are originating from two main classes of studies. First, 38 
studies (21%) can be categorized as randomized controlled trials 
(RCTs) and open-label extension studies (mostly these studies 
are part of the phase I/III clinical development of the proposed 
biosimilar, but also include for example the NOR-SWITCH 
trial).24 An overview of the study design and switch results of 
this first class of switch studies, across products and disease 
areas, can be found in Table 2. Second, the bulk of the data 
(N  =  140; 79%) is originating from studies conducted in the 
real-world setting (i.e.,  real-world evidence (RWE), defined as 
nonrandomized studies outside the biosimilar candidate’s clini-
cal development). The identified RWE consists of parallel arm, 
nonrandomized, nonblinded studies and predominately studies 
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following a single arm design (i.e., the total patient cohort that 
(systematically, sometimes driven by procurement decisions) 
switches from the RP to the biosimilar, without a comparator 
arm). Further, registries, such as the DANBIO registry for the 
switch from the infliximab RP to CT-P13 and the switch from 
the etanercept RP to SB4, were identified.
In addition to efficacy and safety outcomes, the measurement of 
trough levels (TLs) and ADAs upon switching was screened. TLs 
and ADAs were reported in 71 of 178 studies. Figure 3 shows the 
number of studies reporting on ADA and/or TL across products.
Based on the conclusion of the authors, the majority of the stud-
ies did not identify major efficacy, safety, or immunogenicity issues 
due to switching from a RP to its biosimilar version.
Study-specific results per product are further discussed below 
and shown in Tables S3–S11 in the online Supplementary 
Information.
Figure 1 Overview of number of switch studies across products. 
Figure 2 Overview of different switch study designs. B, biosimilar; R, reference product; rand., randomization.
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SWITCH STUDIES FOR SOMATROPIN
One biosimilar (Omnitrope) of somatropin (RP Genotropin), 
a rhGH, has been authorized in the EU.2 Eight switch studies 
from the RP of somatropin to Omnitrope have been identified 
(Table S3 in the online Supplementary Information). Seven 
studies consisted of a single arm study design and one was a 
randomized open-label phase III trial.25 All studies consisted 
of a single switch from the RP to the biosimilar. Overall, none 
of these studies indicated safety or efficacy issues related to 
switching.
SWITCH STUDIES FOR EPOETIN ALFA/ZETA
Five biosimilars (representing two unique products) of epo-
etin alfa (RP Eprex) are EU approved (Epoetin Alfa Hexal/
Abseamed/Binocrit, and Silapo/Retacrit).2 The marketing 
authorization holder of Silapo/Retacrit requested another 
INN for their active substance (i.e., epoetin zeta).2 A total of 
20 switch studies were identified for epoetin alfa and epoetin 
zeta (Table S4 in the online Supplementary Information). 
Five switch RCTs were identified, of which one trial can be con-
sidered as a multiple switch study.18,26–29 In this study, patients 
were treated with an originator prior to enrollment. Upon the 
start of the trial, a part of these patients were switched to a bi-
osimilar, followed by a second switch to the originator during 
the study duration.18 Further, 14 single arm studies were identi-
fied. One of the studies, a retrospective matched control study 
in hemodialysis patients, demonstrated a dosing penalty (i.e., re-
quiring higher doses to maintain Hb level) after switching.30 In 
this study, 163 patients were switched and followed up during 
24 weeks. Higher doses of 40% were reported to be required to 
maintain anemia control.30
SWITCH STUDIES FOR FILGRASTIM
Seven biosimilars (representing four unique products) of filgras-
tim (RP Neupogen) have been approved in the EU (i.e., Zarzio/
Filgrastim Hexal, Tevagrastim/Ratiograstim, Nivestim, and 
Grastofil/Accofil).2
Five studies included a switch from the filgrastim RP to a fil-
grastim biosimilar (Table S5 in the online Supplementary 
Information). Three of these consisted of a randomized phase III 
trial design, of which one study included a multiple switch.31,32,23 
The other two studies consisted of a retrospective chart/database 
review. Overall, none of these studies indicated safety or efficacy 
issues related to switching. In all these studies, patients were treated 
with chemotherapy.
SWITCH STUDIES FOR INSULIN GLARGINE/LISPRO
Two unique biosimilars of insulin glargine (RP Lantus) are ap-
proved in the EU (i.e., Abasaglar and Semglee).2 Insulin lispro 
Sanofi is an EU-approved biosimilar of the insulin lispro RP 
(Humalog).2
Four studies incorporating a switch between the insulin 
glargine RP and a biosimilar were identified (Table S6 in the 
online Supplementary Information). One of these studies, 
based on a retrospective chart review, indicated an increase in 
insulin dosage by 2.4 units after switching 24 patients to the Au
th
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biosimilar.33 The results of another retrospective chart review, 
of 73 patients switched from Basalin to Lantus showed further 
reductions in blood glucose, although the insulin glargine dose 
did not increase.34 The hypoglycemia incidence was low during 
both Basalin and Lantus treatment (2.4% vs. 1.2%, respectively), 
with no cases of severe hypoglycemia. Authors concluded that 
further studies are needed to verify these findings.34 Basalin is 
not approved in the EU or in the United States, thus, not to be 
considered a true biosimilar evaluated by a stringent regulatory 
framework. A lack of true biosimilarity could, thus, potentially 
explain the observed pre- and post switch differences. The retro-
spective design poses further a limitation to the interpretation of 
the results. No insulin lispro switch studies were identified.
SWITCH STUDIES FOR ANTI-TNFS
The study parameters and results of the RCT and open-label switch 
studies for infliximab, adalimumab, and etanercept are shown in 
Table 2. A complete overview of all the anti-TNF switch stud-
ies can be found in Tables S7–S9 in the online Supplementary 
Information.
Infliximab
Four biosimilars (representing three unique products) of inflix-
imab (RP Remicade) have been EU-approved (i.e., Remsima/
Inflectra, Flixabi, and Zessly).2 One hundred studies incorpo-
rating a switch between the RP and one of its biosimilars have 
been identified. The study parameters and results of the switch 
studies for infliximab can be consulted in Table S7 in the online 
Supplementary Information.
Results of RCTs and extension trials investigating the 
switch from the infliximab RP to a biosimilar
Most RCTs investigating switching from the infliximab RP to 
one of its biosimilars incorporated a switch after the assessment 
of the primary trial end point in the main clinical trial (i.e., in an 
extension trial). Extension studies of the pivotal PLANETAS and 
PLANETRA trials, investigating the switch from the infliximab 
RP to CT-P13 (Remsima/Inflectra) in patients with rheumatoid 
arthritis (RA) and ankylosing spondylitis respectively, showed no 
reduced efficacy nor an increase in adverse events (AEs) between 
the maintenance and the switch groups.35,36 However, during the 
second year of the PLANETAS extension study, the incidence 
of more than one treatment-emergent adverse events (TEAEs) 
was 48.9% vs. 71.4% patients in the maintenance CT-P13 and 
the RP-CT-P13 switch group, respectively.36 ADA incidence 
and hypersensitivity reactions observed in both extension tri-
als (PLANETRA and PLANETAS) did not significantly differ 
between maintenance and switch group.35,36 Further, a phase III 
double-blind RCT investigating the single switch from infliximab 
RP to SB2 (Flixabi) has been conducted in patients with RA (94 
patients switched).37 The efficacy, safety, and immunogenicity 
profiles were reported to remain comparable between groups up 
to the end of 24 weeks of follow-up, indicating that there were no 
TEAEs or clinically relevant differences after switching from the 
RP to SB2.37 The landmark NOR-SWITCH trial, supported by 
the Norwegian government, is an independent randomized, dou-
ble-blind, noninferiority (NI) study with 52 weeks of follow-up.24 
The  NOR-SWITCH trial  aimed to evaluate maintenance of 
efficacy and the monitoring of AEs in patients after the switch 
from the infliximab RP to CT-P13 in comparison with the effi-
cacy and AEs in patients under continued treatment with the RP. 
Patients across the six therapeutic indications of infliximab were 
included (i.e., patients with RA, spondyloarthritis, psoriatic ar-
thritis, chronic plaque psoriasis, Crohn’s disease (CD), and ulcer-
ative colitis (UC)). The primary end point of the study was disease 
worsening (determined by worsening in disease-specific compos-
ite measures or a consensus about disease worsening between the 
investigator and the patient, which lead to a major change in the 
treatment). The NI margin was set at 15% at 52 weeks, assuming 
30% disease worsening in each group. Almost 500 adult patients 
on stable treatment with the RP for at least 6  months were 1:1 
randomized to switch to CT-P13 or to continue treatment with 
the RP. Disease worsening occurred in 26% of patients in the RP 
group and in 30% of patients in the CT-P13 group. The lower limit 
of the 95% confidence interval of the adjusted risk difference fell 
within the predefined NI margin of 15% (–4.4%; 95% CI –12.7 to 
3.9), showing that switching from the RP to CT-P13 was not in-
ferior to continued treatment with the RP. Further, the frequency 
of serious AEs, overall AEs, and AEs leading to discontinuation 
was similar between groups. Serum trough concentrations and 
the incidence of ADAs were also similar between groups. A draw-
back of this study is the fact that it was not powered to show NI in 
Figure 3 Number of studies with ADA and/or trough level measurements. ADA, antidrug antibody; TL, trough level.
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the individual therapeutic indications.24 Patients who completed 
the 12-month treatment were asked to enter in an open-label fol-
low-up study in which all patients received CT-P13 for 26 weeks. 
The extension study did not show any difference between patients 
who maintained CT-P13 compared with patients who switched 
from the RP to CT-P13.38 Further, the single switch from the in-
fliximab RP to BOW015 was investigated in an open-label exten-
sion phase III trial in patients with RA.39 The impact of a single 
switch from the RP to PF-06438179/GP1111 (Zessly) was inves-
tigated in an RCT phase III trial40 and the single switch from RP 
to CT-P13 was investigated in an open-label extension phase I/II 
trial41 and in a RCT phase III trial.42 Overall, the switch did not 
negatively affect efficacy, safety, or immunogenicity outcomes in 
these studies.
Real-world clinical studies investigating the switch from the 
infliximab RP to a biosimilar
Several studies (91/100) aimed to collect real-world data about the 
switch from the infliximab RP to one of its biosimilars, mostly 
for CT-P13 (first approved infliximab biosimilar). An overview of 
the study design and results of these studies is available in Table 
S7 in the online Supplementary Information. A study based 
on the data from the DANBIO registry reported outcomes of a 
systematic, nationwide switch from the infliximab RP to CT-P13 
of Danish patients with RA, spondyloarthritis, and psoriatic ar-
thritis under infliximab treatment.43 Investigators reported that 
the disease activities were similar 3 months pre- and post switch. 
After 1 year of follow-up, ~ 84% of patients were still under CT-
P13 treatment, which was lower than in the NOR-SWITCH trial 
(96%). Authors indicated that this difference could be explained 
by the real-world setting of the study. The 1-year retention rate was 
slightly lower (3.4%) compared with patients treated with the RP 
in a historic cohort.43
Some infliximab switch studies reported a difference in efficacy, 
safety, immunogenicity, retention rate, or product dosage before 
and after switching or between the switch and maintenance group 
in their final conclusion.44–48 Multiple studies reported a higher 
number of discontinued treatment, mainly driven by worsening in 
patient-reported outcomes, without changes in objective parame-
ters (e.g., in TL, ADAs, and C reactive protein). Mostly, authors 
concluded that this was probably driven by nocebo effects (i.e., 
patients’ negative expectations leading to experienced AEs or a per-
ceived decrease in response49).44–47
Adalimumab
Eight biosimilars (representing five unique products) of adali-
mumab (RP Humira), have been approved in the EU (i.e., 
Imraldi, Solymbic/Amgevita, Halimatoz/Hefiya/Hyrimoz, 
Cyltezo, and Hulio).2 Seven switch studies from the RP to 
one of its biosimilars were identified (Table S8 in the online 
Supplementary Information). These are all double-blind or 
open-label extension studies of phase III trials as part of the 
biosimilar development program. Two studies investigated 
switching from the RP to ABP 501 (Amgevita/Solymbic) in 
two different patient settings (RA and plaque psoriasis).50,51 
The trial in RA was a phase III open-label extension trial, 
incorporating a single switch from the RP to ABP 501 in 237 
patients with a follow-up of 46 weeks.50 The trial by Papp and 
colleagues investigated a single switch from the RP to ABP 501 
in 77 patients with moderate to severe plaque psoriasis, during a 
phase III RCT.51 Data from both trials indicated that safety, in-
cluding immunogenicity, was similar among groups after a sin-
gle switch.50,51 One phase III RCT trial investigated the single 
switch from the RP to SB5 (Imraldi) in 125 patients with RA. 
Efficacy, safety, and immunogenicity profiles were reported to 
be comparable between groups. It was stated that no TEAEs 
or clinically relevant immunogenicity arose by switching.52 
The trial by Blauvelt and colleagues consisted of a sequence of 
four switches (multiple switch design; switch at week 17, 23, 29, 
and 35) between the RP and GP2017 (126 patients switched, 
34  weeks follow-up after initial switch at week 17). Efficacy, 
safety, and immunogenicity were reported to be similar among 
the switch and nonswitch groups.19 A randomized open-label 
extension study investigated the impact of a second switch 
at week 48, after the first switch at week 24 during the dou-
ble-blinded part of the study, between the RP and FKB327 in 
patients with RA. The interim results suggest that safety, effi-
cacy, and immunogenicity were comparable between the main-
tenance and switch groups.20 Further, for both CHS-1420 and 
BI695501, a randomized double-blind RCT investigated a sin-
gle switch from the RP. Overall, no efficacy, safety, or immuno-
genicity issues were reported.53,54
Etanercept
Benepali and Erelzi are two unique EU-approved biosimilar ver-
sions of etanercept (RP Enbrel).2 In total, 25 etanercept biosim-
ilar switch studies have been identified. Five of these consist of a 
double-blind or open-label RCT of which four were conducted 
in rheumatology indications.55–58 The other study consisted of 
a multiple switch double-blind RCT (EGALITY) investigating 
repeated switching between the etanercept RP and GP2015 in 
patients with plaque psoriasis.21 Patients were switched at week 
12, 18, 24, and 30 and followed up to 52 weeks. It was concluded 
that the repeated switches between the RP and GP2015 had no 
negative impact on safety or immunogenicity outcomes.21 Of 
20 RWE studies, 18 were conducted in rheumatology and 2 in 
dermatology. A multiple switch was performed between the RP 
and SB4 with patients with rheumatic disease in clinical prac-
tice, switching from RP to SB4 and back again after approxi-
mately a year and one half.22 It was reported that the multiple 
switch did not negatively impact the disease activity. However, 
a high proportion of patients discontinued SB4 after the first 
switch. The authors attributed this to nocebo effects, as no 
worsening in disease activity measures was observed.22 In a sin-
gle switch study from etanercept RP to SB4 in patients with 
rheumatic disease, 39% of patients experienced side effects.59 
The authors underlined the need to improve the patients’ ex-
perience of switching as a way to decrease side effects.59 This 
need was echoed in a single switch from etanercept RP to SB4 
in patients with rheumatic disease in a single center in France.60 
Approximately 17% of patients discontinued the biosimilar, 
whereas no objective parameter concluded a lower efficacy or a 
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decreased safety profile. The authors suggested that this could 
be explained by the open study design (i.e., patients were aware 
of the switch).60 The study parameters and results of the switch 
studies for etanercept can be consulted in Table S9 in the on-
line Supplementary Information.
SWITCH STUDIES FOR FOLLITROPIN ALFA
Two biosimilars (representing two unique products) of follitro-
pin alfa (RP GONAL-f) have been authorized in the EU (i.e., 
Ovaleap and Bemfola).2 One open-label extension phase III single 
switch study from follitropin alfa RP (GONAL-f) to Ovaleap has 
been reported, which can be consulted in Table 2 or Table S10 in 
the online Supplementary Information. The study results were 
overall in support of the safety and efficacy of the switch.61
SWITCH STUDIES FOR LOW-MOLECULAR-WEIGHT 
HEPARINS
Two biosimilars (representing one unique product) of enoxaparin 
(RP Clexane) have been authorized in the EU (i.e., Inhixa and 
Thorinane).2 No switch studies between the RP of enoxaparin 
and an enoxaparin biosimilar have been identified.
SWITCH STUDIES FOR MONOCLONAL ANTIBODIES IN 
ONCOLOGY
The study parameters and results of the RCTs and open label 
switch studies for rituximab and trastuzumab are shown in 
Table 2. A complete overview of all rituximab and trastuzumab 
biosimilar switch studies is shown in Table S11 in the online 
Supplementary Information.
Rituximab
Six biosimilars (representing two unique products) of rituximab 
(RP Mabthera) have been approved in the EU (i.e., Truxima/
Ritemvia/Blitzima/Rituzena (CT-P10), and Riximyo/Rixathon 
(GP2013)).2 Seven switch studies have been identified. Five studies 
were conducted in the scope of the clinical biosimilar development 
(i.e., the single partial crossover switch to BCD-02062; a Russian 
product, not approved in the EU or the United States, thus not to 
be considered a true biosimilar evaluated by a stringent regulatory 
framework), an open-label extension phase I study for CT-P10,63 an 
open-label extension phase III study for CT-P10,64 a double-blind 
RCT for GP2013,65 and a randomized extension phase I study for 
PF-05280586.66 All studies  were performed in patients with RA. 
None of these studies detected safety, efficacy, or immunogenicity 
issues related to switching. In addition, results of two RWE ritux-
imab switch studies were reported, of which one was conducted in 
non-Hodgkin’s B cell lymphoma and one in RA.67,68 The study of 
Nisar et al. switched 29 patients with RA to CT-P10.68 It was re-
ported in abstract that 20% of these patients had severe serum sick-
ness with LOE and loss of confidence in the treatment. Authors 
concluded that they support routine switching to the rituximab bio-
similar, however, close monitoring needs to be applied.68
Trastuzumab
Five unique biosimilars of trastuzumab (RP Herceptin) have been 
approved in the EU: Herzuma, Kajinti, Ogivri, Ontruzant, and 
Trazimera.2 For one biosimilar (Kanjinti), a single switch was 
incorporated during the phase III trial in early breast cancer pa-
tients.69 Efficacy, safety, and immunogenicity was reported to be 
comparable between the maintenance and switch group.69 No 
RWE studies were identified.
CURRENT SWITCH EVIDENCE – LEARNINGS AND 
CONSIDERATIONS
This paper provides a systematic overview and a critical insight in 
the currently available evidence about switching from a biological 
RP to its biosimilar(s).
Several reviews of switching studies from biological RPs to 
biosimilars have been published. The first review, in 2012 by 
Ebbers and colleagues, investigated switching for erythropoi-
etins, rhGHs, and granulocyte colony stimulating agents,14 
products for which, at that time, a biosimilar was approved. 
Since then, many other biosimilars, for different RPs across sev-
eral therapeutic classes, have been approved, including the more 
complex mAb biosimilars.2 Further, other reviews have been 
conducted but these mostly focussed on one specific product 
class or therapeutic area.17,70,71 Two other systematic literature 
reviews (McKinnon and Cohen72,73) have been published that 
included switch studies derived from multiple product classes 
and disease areas. Switch  studies were included until June of 
2017 in these reviews. Although both reviews, with the exemp-
tion of some data points (e.g., the paper of McKinnon excluded 
studies in which <  20 patients were switched), include similar 
data, the conclusion of the authors on the safety of switching was 
divergent.72,73 Unsurprisingly, as the topic of switching is heav-
ily debated, and the heterogeneity of study designs leaves some 
room for interpretation. Cohen and colleagues concluded that 
the body of evidence provides reassurance that switching is not 
associated with immunogenicity-related safety concerns or de-
creased efficacy.73 The review by McKinnon and colleagues con-
cluded that evidence gaps remain around the safety of switching, 
underlining the need for more robust studies.72
This paper aims to provide a systematic and exhaustive review 
of all switch studies between biological RPs and their respective 
biosimilars, and this across therapeutic classes and products for 
which the European Commission (EC) has approved a biosimilar, 
updating and adding to the existing literature studies. This review 
provides an exhaustive overview of existing switch studies from bi-
ological RPs to biosimilars up to June 2018.
This systematic literature review applied a holistic approach, 
meaning every study describing a switch from a RP to a biosimilar 
was included. This was done in an effort to give a complete and 
unselected/unbiased overview of the existing studies. This can be 
seen as a strength but also as a limitation of the review, as regardless 
of the sometimes very limited sample size or incomplete method-
ology and its associated low(er) level of evidence, studies were in-
cluded. Further, studies that only reported data in abstract and/or 
in poster were included as well. This to capture the most recent and 
most complete data about switching as many data are recent and 
still emerging. Data from abstracts and posters should be consid-
ered as preliminary until published in full-text in a peer-reviewed 
journal. A major limitation of this study was the heterogeneous 
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character of the individual studies, limiting the comparability be-
tween studies and making a formal meta-analysis impossible. Most 
of the studies and data were descriptive in nature. Only a few stud-
ies, mostly (extension) clinical studies in the development program 
of a biosimilar, were powered or designed to detect differences in 
efficacy. Other limitations include potential publication bias of in-
dividual switch studies.
THE DESIGN OF SWITCH STUDIES AND THEIR QUALITY
Based on the currently available data, there are no robust data that 
indicate that switching from an RP to its biosimilar leads to major 
safety issues. However, the design of many studies is not suffi-
ciently sensitive or not methodologically robust enough to iden-
tify and, thus, exclude differences in the occurrence of rare safety 
events or differences in efficacy.
LOE during maintenance treatment is quite common for 
certain therapeutic products and disease fields. For example, 
between 23% and 46% of patients treated with an anti-TNF in 
inflammatory bowel disease (IBD) loses response to treatment 
over time.74 Juillerat and colleagues identified a dropout rate of 
18% during the first year of treatment, followed by 8% and 10% 
during years 2 and 3 for patients with IBD treated with inflix-
imab.75 In the case of an experienced or observed decrease or loss 
in response during a single arm switch study, it is difficult to de-
termine if this is due to (i) the mere “normal” decrease in treat-
ment response over time, (ii) due to nocebo effects of the patient 
(experienced inefficacy or decreased efficacy), or (iii) due to an 
hypothesized  increased immunogenicity. The evidence derived 
from single arm studies is thus limited. The use of objective end 
points, such as the measurement of ADAs or TLs, can partially 
address the interpretative limitation of single arm studies in case 
of identified efficacy or safety signals. The same argument can 
be made for registries. Registries, although informative of nature, 
can be difficult to interpret as they lack such a comparator arm 
and may not be able to adjust for all confounding variables.
Not only studies without a parallel arm have limitations for the 
interpretation of data, well-designed clinical trials can also be in-
sufficiently sensitive to detect small differences in efficacy.76 Louis 
and colleagues investigated the risk of relapse of patients with CD 
in prolonged remission after the discontinuation of infliximab 
treatment.76 After a follow-up period of 28 months, more than half 
of the patients were still in remission. The 1-year relapse rate was 
43.9% ± 5.0%.76 A potential decrease in response after switching 
could, thus, potentially go undetected in some cases due to sus-
tained remission of treatment on the RP in some patients. Further, 
most switch trials have a relatively short follow-up period, mostly 
too short to identify rare immunological events. Further, the sam-
ple size of the identified switch studies and RCTs was mostly too 
small to identify rare AEs.
The bulk of the switch data in the real-world setting consists of 
monitored switches from the infliximab RP to CT-P13, explained 
by the fact that CT-P13 was the first infliximab biosimilar, and 
mAb biosimilar in general, to be introduced on the market. Most 
of these studies were conducted in IBD. This could be interpreted 
as an effort of individual hospitals and pharmaceutical companies 
to gather clinical evidence about the use of infliximab biosimilars 
in gastroenterology, given that the product received approval for 
CD and UC based on the principle of extrapolation of indications.
The body of identified switch studies is heterogeneous in its 
design, and, by consequence, in the quality of the generated evi-
dence, and cannot exclude every potential risk. On the one hand, 
the gathered data may provide a general indication that switch-
ing seems not to be associated with major efficacy, safety, or im-
munogenicity issues. On the other hand, findings with respect to 
switching should be product-specifically and disease-specifically 
interpreted and cannot be generalized to other products or other 
diseases, given different immunological complexities of the differ-
ent products, different disease states, and different concomitant 
treatments.
IMMUNOGENICITY REPORTING
The increase in immunogenicity is one of the main voiced con-
cerns surrounding switching from a biological RP to a biosimilar 
(or vice versa). Immunogenicity is evaluated in the development 
of every biosimilar, as per regulatory requirements.77 Further, the 
safety of biosimilars is monitored postmarketing by regulatory au-
thorities, as is the case for biological medicines in general.10
ADA determination, however, is not common in clinical prac-
tice for many biologics (as also shown by the relatively low level 
of ADA reporting in the real-world switch studies in this review). 
Taken into account that, depending on the product or the disease 
state, the occurrence of ADAs (for example, due to their transient 
nature) not always translates in a negative clinical outcome, such as 
the incidence of AEs or LOE, the measurement of TLs may be use-
ful to assess the impact of immunogenicity on clinical outcomes. 
The measurement of ADAs and/or TLs could provide an objective 
measurement to help clarify the cause of unexpected AEs or a de-
creased treatment response in the real-world setting (without any 
comparator arm).
Biological medicines, such as infliximab and rituximab, are often 
concomitantly used with methotrexate, which can limit a potential 
immunogenic response. This should be taken into account when 
extrapolating switch findings to other disease indications in the ab-
sence of such a concomitant treatment.
CROSS-REACTIVITY OF ANTIDRUG ANTIBODIES BETWEEN 
RPS AND BIOSIMILARS
Several studies have investigated the immunogenic profile of the 
infliximab RP and one of its biosimilars CT-P13 (Remsima/
Inflectra) and the cross-reactivity of ADAs between both prod-
ucts.7,78–80 These studies provided similar results in support of 
the immunogenic similarity between the  infliximab RP and 
CT-P13 in IBD80,78 or rheumatic diseases.7,79 It was shown that 
ADAs against the RP recognized and reacted to the biosimilar in 
a similar way, indicating that these products share similar immu-
nodominant epitopes. Additional epitopes (e.g., due to differences 
in the glycosylation pattern, impurities, or aggregations) may not 
be excluded, but data suggest that the epitopes that are involved 
in the immune response to the RP are also present for CT-P13.7 
Further, the regulatory quality standards applied for biosimilars 
preclude meaningful impurities or aggregations. It is obvious that 
patients showing an immunogenic response under treatment with 
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the RP (or biosimilar) should not be switched to the biosimilar 
(or RP), as the existing ADAs will cross-react with both versions. 
Likewise, ADA-negative patients under treatment with the RP are 
not expected to assert an immune response to the biosimilar when 
switched.80
ADDRESSING THE QUESTION OF SWITCHING IN EUROPE
Different from the FDA in the United States, there is no regu-
latory pathway considering a designation of interchangeability in 
Europe. Further, there is no official position of the EMA about 
switching, interchangeability, or substitution, as this falls within 
the responsibilities of the individual member states. The informa-
tion guide for HCPs, prepared jointly by the EMA and the EC, 
indicates that “there is no reason to believe that harmful immu-
nogenicity should be expected after switching between highly 
similar biological medicines,”10 referring to an article by a group 
of European regulators and members of the Biosimilar Medicinal 
Products Working Party.81 This group of regulators argues that 
switching patients from an RP to a biosimilar or vice versa can 
be considered safe, as there is, in their opinion, no reason to be-
lieve that the immune system would react differently to the bio-
similar compared with the RP, given the fact that they are highly 
similar.81 It is concluded that the demonstration of biosimilarity, 
together with adequate PMS, sufficiently and realistically en-
sures interchangeability of biosimilars in the EU.81 Increasingly, 
guidance about the use of biosimilars in practice and switching 
is provided by national competent authorities and professional 
HCP organizations.15 Several national regulators indicate that 
switching from a RP to a biosimilar is deemed appropriate, pro-
vided that it is done under the supervision of the prescriber, the 
patient is properly informed, the patient is clinically followed up, 
and traceability of the products is ensured.15 Despite an increase 
in guidelines among certain authorities and organizations, the 
confidence among many stakeholders remains low and continues 
to lead to questions. Harmonisation of (national) regulatory guid-
ance and/or scientific recommendations on the use of biosimilars 
and switching may aid the decision making of HCPs and other 
decision makers.
DISCONTINUATION RATES AND THE NOCEBO EFFECT
In several studies,44–48 authors concluded that patients experi-
enced subjective AEs or LOE, potentially explaining the high 
discontinuation rate and the need to switch back to the RP. The 
experienced AEs or LOE were not linked to objective safety sig-
nals and investigators ascribed this to attribution or nocebo ef-
fects (i.e., patients’ negative expectations leading to experienced 
AEs or a perceived decrease in response).49
Several studies investigating the perspectives of stakeholders 
identified uncertainty among patients and HCPs about biosim-
ilars and the act of switching from an RP to a biosimilar.5,6 The 
potential nocebo effect upon switching highlights the importance 
of a good knowledge and understanding among physicians and 
patients about biosimilars. The information provided to patients 
may play a role in the perceived outcome of the treatment. Well-
informed HCPs should inform patients about the product they 
receive in an evidence-based manner. The nocebo effects further 
highlight the importance of shared, evidence-based decision mak-
ing between the physician and the patient. Strategies mitigating the 
nocebo effect may improve patient outcomes and discontinuation 
rates.49
FURTHER CONSIDERATIONS: MULTIPLE SWITCHING, 
SWITCHING BETWEEN BIOSIMILARS OF THE SAME 
REFERENCE PRODUCT, AND PRODUCT TRACEABILITY
Until now, a limited number of studies report about multiple switch-
ing.18–23 Overall, no clinically meaningful differences in efficacy, 
safety, or immongenicity were reported in the available multiple 
switch studies. The question about multiple switching among HCPs 
is increasingly raised, indicating the need for information in this 
field. Following the FDA interchangeability guidance,13 multiple 
switch studies evaluating two or more alternating exposures may 
emerge in the future. Because multiple, independently developed bi-
osimilars of the same RP have been approved and are on the market, 
switching between biosimilars of the same RP is a possibility as well. 
However, not every biosimilar of the same RP is a distinct product. 
Indeed, some biosimilars are licensed under different brand names 
but contain exactly the same product (e.g., Remsima and Inflectra 
contain both the active substance CT-P13, and Blitzima, Ritemvia, 
Rituzena, and Truxima contain CT-P10). So far, no clinical  data 
about switching between biosimilars of the same RP were identified.
To ensure adequate product traceability, it is of importance to 
document the specific biological product that is prescribed, includ-
ing brand name, INN, and batch number when prescribing biolog-
icals or when reporting any AEs. Postmarketing pharmacovigilance 
remains key for both RPs and biosimilars to track ongoing safety 
and immunogenicity and detect potential safety signals. PMS is 
particularly important to identify rare immunological events that 
can only be detected after a long follow-up period in large patient 
numbers. To ensure an optimal use and value of registries, brand 
names and batch numbers need to be included to correctly identify 
the medicine if any product-specific efficacy, safety, or immunoge-
nicity concerns should arise.10
RESIDUAL UNCERTAINTY
It has been argued that switching could lead to increased immu-
nogenicity, due to potential differences in epitopes between the 
biosimilar and the RP. Relevant differences in this regard, such as 
quality differences in terms of high-molecular-weight aggregates 
or impurities, would, however, be excluded by the robust regu-
latory evaluation of biosimilars (i.e., such differences would pre-
clude biosimilar approval).
The scientific principles underpinning the biosimilarity exer-
cise are, in fact, based on the comparability concept, a well-estab-
lished scientific principle, which is used to evaluate the differences 
of a biological product before and after a manufacturing change 
(biologicals frequently undergo manufacturing changes after ap-
proval82).81,83,84 Demonstrating comparability ensures that the 
products pre- and post manufacturing change are highly similar and 
allows regulators to conclude that any observed differences have no 
adverse impact on efficacy or safety of the product. Demonstrating 
biosimilarity generally requires a more comprehensive comparison 
than manufacturing changes. The latter rarely require clinical data, 
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but for major changes, such as a change of cell-line, large scale clin-
ical studies may be required.81 Overall, the extensive experience 
gathered in regulating manufacturing changes of reference prod-
ucts has provided assurance to regulators about the risks associated 
with switching from one highly similar version of a biological to 
another.81
Although the switch studies presented in this review cannot ex-
clude every potential risk associated with switching from a RP to a 
biosimilar, as clinical studies are variable and insensitive to assess the 
impact of minute differences, they do not corroborate the voiced 
concerns of increased immunogenicity due to switching. Therefore, 
discouraging a single switch from a RP to a biosimilar is deemed 
disproportional compared with the residual uncertainty associated 
with such a switch. Further, residual uncertainty, to a certain extent 
inherently associated with the use of any biological medicine or any 
medicine in general, can never be fully excluded. The current body 
of switch data, together with the robust biosimilar approval path-
way, however, helps to limit the residual uncertainty to an accept-
able level.
CONCLUSION
Based on the currently available switch data of over 170 studies, 
there are no robust data that indicate that switching from a ref-
erence biological to a biosimilar is related to any  major efficacy, 
safety, or immunogenicity issues. The switch studies cover dif-
ferent molecules across different therapeutic classes. Most of the 
currently available data refer to switching for anti-TNFs and, 
more specifically, from the infliximab RP to CT-P13 (Remsima/
Inflectra). Due to a small sample size and generally short follow-up 
period, most of the identified studies are, however, insufficiently 
sensitive to detect and, thus, exclude rare AEs. Data on multiple 
switching and switching between biosimilars for the same RP is 
so far scarce or not present. Although the decision to switch must 
be made on an individual and product-specific level, this review 
on switching between biological RPs and biosimilars supports 
that, for the products studied, a single switch is not intrinsically 
linked to an increase in immunogenicity, safety, or efficacy issues. 
Any decision to switch should involve the prescriber and attention 
must be paid to the mitigation of a potential nocebo effect.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
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